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A B S T R A C TObjective: Resource allocation informed by cost-utility analysis
requires that the benefits be comparable across patient groups and
interventions. One option is to recommend the use of one generic
utility measure, but this raises the issue of comparability when the
preferred measure is inappropriate or unavailable. Many cancer trials
do not include generic measures such as the EuroQol five-dimensional
(EQ-5D) questionnaire and instead include condition-specific mea-
sures and use these to generate utility estimates. We analyze the
comparability of generic, condition-specific, and mapped utility
values for a multiple myeloma cancer patient data set. Methods:
Generic EQ-5D, condition-specific EORTC-8D, and EQ-5D utility values
mapped from the EORTC QLQ-C30 were compared by using psycho-
metric and statistical analysis to determine discrimination across
severity groups, responsiveness, and agreement. Results: Generic,
condition-specific, and mapped utility estimates were responsive over
time and show discriminative validity. The EQ-5D had higher respon-
siveness and detected a greater change across severity groups andnt matter Copyright & 2012, International Society
r Inc.
.1016/j.jval.2012.08.2201
sheffield.ac.uk.
ndence to: Donna Rowen, Health Economics and De
Court, 30 Regent Street, Sheffield S1 4DA, UK.treatment periods than did the EORTC-8D but has a higher proportion
of responses at full health (12.8%). Differences in the EQ-5D and the
EORTC-8D were due at least in part to differences in the classification
system. Mapped EQ-5D estimates had a smaller SD and do not reflect
the severe range of health states reported by using the EQ-5D.
Conclusions: Our findings suggest that condition-specific EORTC-8D
or mapped EQ-5D utility estimates are broadly comparable to directly
obtained EQ-5D utilities for a multiple myeloma patient data set.
However, EORTC-8D estimates captured changes in quality of life for
patients in mild health states that were not captured by the EQ-5D,
but estimated lower utility gains than did the use of the EQ-5D
directly.
Keywords: condition-specific measures, mapping, preference-based
measures, QALYs, utility.
Copyright & 2012, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Resource allocation informed by economic evaluation using
cost-utility analysis has become increasingly popular in recent
years. This analysis requires that the measures of benefit and cost
for each evaluation be comparable across both different patient
groups and different interventions. Payers in various European
jurisdictions prefer the expression of benefit in quality-adjusted
life-years (QALYs), which are a measure of both quantity and
quality of life (QOL). Often, generic preference-based measures
such as the EuroQol five-dimensional (EQ-5D) questionnaire [1],
health utilities index 3 [2], or six-dimensional health state short
form (derived from short form 36 health survey) [3,4] are used to
calculate the ‘‘Q’’ component of the QALY. It is well documented,
however, that different generic measures produce different
results when applied to the same patient group at the same point
in time [5]. This raises issues for comparability, and one solution
is to recommend the use of a single measure for all evaluations.
This is the approach taken by the National Institute of Health andClinical Excellence (NICE) [6] where the most commonly used
generic measure, the EQ-5D, is recommended for use in all
technology appraisals. This raises the question of how utility
values should be generated if the EQ-5D is either unavailable or
inappropriate, and the comparability of evaluations undertaken in
these circumstances.
Cancer is one condition in which it remains unclear whether
the generic EQ-5D is appropriate, but the issue is further com-
plicated by the fact that the EQ-5D is often unavailable because
many cancer trials do not include it. NICE state that if a measure
is thought inappropriate, empirical evidence should be provided
demonstrating why it is inappropriate, covering properties such
as content validity, construct validity, responsiveness, and relia-
bility. A recent report argues that the EQ-5D may not be suffi-
ciently sensitive to capture changes in the health status of cancer
patients, as, for example, there is no EQ-5D dimension to
specifically capture changes in vitality or energy [7]. There is
little guidance, however, provided by NICE or similar agencies of
when a measure can be deemed inappropriate for a patient groupfor Pharmacoeconomics and Outcomes Research (ISPOR).
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guidance. If the EQ-5D is inappropriate, NICE states that other
measures can be used [6].
Clinicians and researchers often choose to include condition-
specific profile measures in trials rather than generic preference-
based measures such as the EQ-5D. Condition-specific profile
measures, such as the EORTC QLQ-C30, are often included because
these capture the effects of interventions across a wide range of
relevant symptoms, side effects, and aspects of functioning and QOL
and their validity is well established. These profile measures have
great clinical utility and are recommended by the US Food and Drug
Administration [8], whereas the EQ-5D is recommended for effec-
tiveness studies and economic evaluation and can be viewed as
being an additional burden for completion for patients who are very
unwell. These condition-specific profile measures, however, typically
provide a description rather than a valuation of health and cannot be
used to populate cost-effectiveness models. In recent years, there
has been a growth in preference-based measures derived from
existing condition-specific measures that enable these measures to
be used directly to generate utilities. [9–11] The EORTC-8D is a
recently developed condition-specific preference-based measure
derived from the EORTC QLQ-C30 for use in patients with cancer
[12]. This measure allows a utility estimate to be generated for
every individual each time the EORTC QLQ-C30 is used and enables
the direct estimation of utility without placing any burden on
patients to complete an extra measure or additional questions.
Mapping is an alternative method that can be used to obtain utility
values when only a condition-specific non–preference-based mea-
sure was included in the trial. Mapping applies the statistical rela-
tionship between, for example, the QLQ-C30 and the EQ-5D to obtain
predicted EQ-5D values from QLQ-C30 data. This relationship is
typically obtained by estimating regressions on a separate data set
that has patient characteristics similar to those of the trial. Published
mapping algorithms are available that map the condition-specific
QLQ-C30 onto the EQ-5D, and these algorithms can be applied to the
trial data set to produce EQ-5D estimates. If the EQ-5D is unavailable
in a trial, NICE [6] recommends that either mapping or other
validated measures be used to produce utility values. NICE stipulates
that the mapping must be based on empirical data and the other
measures should have valuation methods that are comparable to
those used for the EQ-5D (Measuring and Valuing Health [MVH] tarif)
[13]. The validity of mapping has been questioned, not least because
it relies on substantial overlap between both measures. For an
overview of recommendations for the development and use of
mapping algorithms, see Longworth and Rowen [14].
A small number of studies have examined the impact of using
mapped EQ-5D estimates rather than directly generated EQ-5D
utilities, finding different results across studies [15–17]. A large
number of studies compare the performance of the EQ-5D with the
performance of other main generic preference-based measures
such as six-dimensional health state short form (SF-36 health
survey) and HUI2 [5], but there are few comparisons of condition-
specific and generic preference-based measures [18]. Furthermore,
as far as the authors are aware, no study has examined the
comparability of all preferred options for use in technology apprai-
sals to agencies such as NICE; although the EQ-5D is the preferred
option, under certain circumstances other generic, condition-spe-
cific, or mapped EQ-5D utility estimates can be used.
This article compares utility values generated by using the
EQ-5D, a condition-specific preference-based measure, and map-
ping for a cancer patient data set. We compare utility values
obtained by using the generic preference-based EQ-5D, the
condition-specific preference-based EORTC-8D derived from the
EORTC QLQ-C30, and three published algorithms mapping
the QLQ-C30 onto the EQ-5D. We further compare the performance
of EORTC-8D and EORTC QLQ-C30 summary scores to determine
whether the EORTC-8D maintains the desirable properties of theoriginal measure. This article seeks to inform researchers and
policymakers in their choice of the source of utility values and
the interpretation of these values regarding discrimination across
severity groups, responsiveness, and agreement.
Summary of Measures
The EQ-5D
The EQ-5D has five dimensions (mobility, self-care, usual activ-
ities, pain/discomfort, and anxiety/depression), each with three
levels of severity ranging from ‘‘no problems’’ to ‘‘severe pro-
blems’’ [1]. The health state classification system describes 243
unique health states and utility values that range from 1 to
0.594 for the UK value set collected in the Measuring and
Valuing Health study [13].
The EORTC QLQ-C30 and the EORTC-8D
The QLQ-C30 is widely used in cancer clinical trials in Europe and
Canada [19] and has been found valid for many cancer condi-
tions. The QLQ-C30 has 30 questions that cover functioning
(physical, role, social, emotional, and cognitive functioning) and
common cancer symptoms (pain, fatigue, nausea, vomiting,
dyspnea, appetite loss, sleep disturbance, constipation, and
diarrhea) plus the financial impact of the disease and treatment
(excluded from analyses here because this is inappropriate for
inclusion in health-related QOL measurement to generate
QALYs). The QLQ-C30 has 14 summary scales ranging from 0 to
100, each representing an aspect of functioning (five summary
scales, higher scores represent higher functioning) or a particular
symptom (nine summary scales, higher scores represent greater
symptoms), with one additional global QOL scale.
The EORTC-8D has eight dimensions (physical functioning,
role functioning, pain, emotional functioning, social functioning,
fatigue and sleep disturbance, nausea, and constipation/diar-
rhea), each with four or five levels of severity. The health state
classification system was derived from 10 QLQ-C30 items and
describes 81,920 unique health states with a range of utility
values from 1 to 0.291 [12].Methods
Utility values were generated by using the available preference
weights for the EQ-5D and the EORTC-8D for each patient at each
time point in the data set. Mapped utility values were also
estimated for each patient at each time point by using published
algorithms described below.
Estimating EQ-5D Utilities by Mapping the QLQ-C30 Onto the
EQ-5D
The easiest way to produce mapped estimates is to use published
algorithms. Nine published algorithms use mapping to produce
utilities by using EORTC QLQ-C30 data, three of which were used
here [15,20,21]. The other six algorithms are not used here
because one article requires FACT data not available in our data
set [22], one article maps to patient time trade-off values rather
than the EQ-5D [23], one article does not publish the mapping
function [24], one article maps to the EQ-5D scored by using the
US value set [25], one article maps to the EQ-5D scored by using
the Korean value set [26], and one article maps to the EQ-5D
scored by using the Dutch value set [27]. Patient valuations of
own health by using preference elicitation techniques such as
time trade-off or visual analogue scales are not preferred by
agencies such as NICE or the Washington Panel of Cost Effective-
ness [28] because public preferences are preferred given that
public funding is often used to provide health care. Patient values
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obtain on patients who are very unwell because to generate
QALYs the utility values must be anchored against death on a full
health-death 1-0 scale. Only algorithms that map to the EQ-5D
scored by using the UK value set are included as any difference
between the observed and mapped values may be due to error or
differences in preferences across different countries. This article
compares different methods for estimating utility values for use
in resource allocation decisions in a single country rather than
different utility values estimated for cross-country comparisons.
The mapping algorithms are summarized in Table 1.
The first algorithm used here is an algorithm by McKenzie and
van der Pol [15], who estimated ordinary least squares (OLS)
regressions on 877 observations from 199 patients with esopha-
geal cancer. The regression equations used here include all 15
functioning scales and symptom scales from the QLQ-C30 to map
onto the EQ-5D. McKenzie and van der Pol also report regressions
that predict EQ-5D responses to each dimension rather than to a
utility score, yet they found that these performed worse and so
they are not used here. The regression model was validated by
using data from 254 patients from a trial on radiotherapy after
breast cancer surgery for low-risk elderly women, finding a mean
difference of 0.014 between observed and predicted EQ-5D
values and that the mean observed EQ-5D value was within the
95% confidence interval of the mean predicted value.
The second algorithm is by Kontodimopoulos et al. [20], who
estimated OLS regressions on 48 patients with gastric cancer.
Explanatory variables included in the model were selected by
using a stepwise inclusion procedure, and the remaining vari-
ables were the physical functioning, emotional functioning, and
global health status scales. The model was validated by using
three split-samples from the estimation sample, finding that
observed EQ-5D values were within the 95% confidence intervals
of predicted values.
The third algorithm is by Crott and Briggs [21], who estimated
OLS regressions with a robust Huber-White variance estimator on
856 pooled observations from 220 patients with breast cancer.
The best-performing regression equation included significant
functioning scales and symptom scales (physical functioning,
emotional functioning, social functioning, pain, insomnia, con-
stipation, and diarrhea) and their significant squared terms. The
model was validated by using nonparametric bootstrapping on
the estimation sample.
Cancer Patient Data Set
The analysis was undertaken for a sample of patients newly
diagnosed with multiple myeloma cancer. The data wereTable 1 – Summary of Mapping Algorithms and EORTC-8D der
Article Study EORTC
QLQ-C30
version
Langu
EOR
QLQ-
and E
Rowen et al. [9] EORTC-8D
derivation
3.0 Eng
McKenzie and van der Pol
[12]
Mapping Not specified Eng
Kontodimopoulos et al.
[20]
Mapping Not specified Gre
Crott and Briggs [21] Mapping 1.0 Var
EQ-5D, EuroQol five-dimensional; NA, not applicable.collected in VISTA, a phase III randomized open-label trial
(ClinicalTrials.gov number, NCT00111319) completed in June
2007. Patients were requested to complete both the EQ-5D and
the EORTC QLQ-C30 at their screening visit, day 1 of each of the
nine cycles of treatment, end of treatment visit, and during the
posttreatment phase (every 6 or 8 weeks) until disease progres-
sion. To remove any differences in analyses due to missing
values, observations are included in the analysis only where
both EQ-5D and EORTC-8D and QLQ-C30 items used in each of
the mapping algorithms are available. The data set used here
contains 5650 observations in total across 674 individuals and 16
time periods (all periods in the trial where n465). The mean age
of the sample was 71.58  5.25, and women comprised 50.8% of
the sample.Analysis
Psychometric and statistical analyses were used to compare the
utility estimates produced by using different methods and EORTC
QLQ-C30 summary scores.Validity: Discrimination across Different Severity Groups
Construct validity is examined by assessing the ability to dis-
criminate between patients with different levels of severity. It is
important that a utility measure or method of producing utilities
can discriminate correctly among groups of different severity as
this determines whether the utility values measure an improve-
ment in QOL due to a health improvement in the condition of
interest. The Karnofsky Performance Scale is reported by the
doctor and classifies patients according to functional impairment
typically by using 10- point markers, where a score of 100
indicates that the patient is normal with no signs of disease
and a score of 0 is equivalent to death [29]. As clinical severity is
conceptually different from QOL, discrimination was also cap-
tured across different groups according to self-reported QOL by
using item 30 from the EORTC QLQ-C30 (‘‘How would you rate
your overall QOL during the past week? Please circle the number
between 1 and 7 that best applies to you, 1 ¼ very poor and
7 ¼ excellent’’). Discrimination was examined by using the sta-
tistical significance of differences by using an overall F test from
an analysis of variance and the sensitivity of differences by using
the standardized effect size (ES). ES was estimated by using the
difference in mean scores between two adjacent subgroups of
study participants with different levels of severity divided by the
SD of scores for the mildest of the two subgroups. Utilities wereivation.
age of
TC
C30
Q-5D
Type of
cancer
Number of
patients
EQ-5D
value set
lish Multiple
myeloma
655 NA
lish Esophageal 877 observations from
199 patients
UK
ek Gastric 48 UK
ied Breast 856 observations from
220 patients
UK
Table 2 – Discrimination across severity groups.
Measure Range of mean  SD across groups
Karnofsky Performance Scale 50-60 60-70 70-80 80-90 90-100
EQ-5D 0.171  0.363 0.320  0.344 0.481  0.303 0.618  0.251 0.724  0.217
EORTC-8D 0.557  0.130 0.641  0.120 0.684  0.123 0.733  0.124 0.795  0.125
McKenzie and van der
Pol–mapped EQ-5D
estimates
0.235  0.249 0.392  0.235 0.487  0.238 0.581  0.230 0.693  0.223
Kontodimopoulos
et al.–mapped
EQ-5D estimates
0.286  0.239 0.448  0.237 0.571  0.227 0.672  0.209 0.792  0.211
Crott and Briggs–mapped EQ-5D
estimates
0.390  0.209 0.563  0.219 0.670  0.199 0.748  0.172 0.811  0.141
EORTC QLQ-C30 functioning
summary scores
11.429  21.682 to
68.571  29.641
31.715  28.926 to
72.002  23.108
43.877  28.523 to
73.428  22.787
57.177  27.978 to
76.602  22.396
70.788  25.573 to
81.908  19.196
EORTC QLQ-C30 symptom
summary scores
74.603  24.189 to
12.857  20.246
58.533  24.536 to
9.353  22.492
51.505  23.648 to
9.740  21.680
44.051  22.466 to
9.730  17.973
33.981  22.648 to
6.117  13.985
EORTC QLQ-C30 global QOL
summary score
32.381  19.985 42.266  20.769 48.972  19.295 54.835  17.070 63.731  17.822
Overall quality of life (EORTC
QLQ-C30 item)
1-2 2-3 3-4 4-5 5-6
EQ-5D 0.025  0.309 0.197  0.340) 0.437  0.294) 0.608  0.230) 0.705  0.210)
EORTC-8D 0.483  0.123 0.580  0.120 0.647  0.114 0.728  0.105 0.787  0.107
McKenzie and van der
Pol–mapped EQ-5D
estimates
0.061  0.191 0.239  0.218 0.397  0.197 0.561  0.186 0.692  0.174
Kontodimopoulos
et al.–mapped EQ-5D
estimates
0.079  0.162 0.271  0.172 0.455  0.149 0.638  0.136 0.793  0.130
Crott and Briggs–mapped EQ-5D
estimates
0.315  0.227 0.488  0.225 0.635  0.202 0.751  0.158 0.807  0.131
EORTC QLQ-C30 functioning
summary scores
12.295  23.158 to
48.361  27.475
23.916  26.912 to
60.015  27.251
39.135  26.620 to
70.296  22.408
54.423  26.351 to
76.096  20.797
67.213  25.466 to
82.638  18.664
EORTC QLQ-C30 symptom
summary scores
84.280  20.906 to
20.219  30.771
70.603  23.428 to
16.741  28.276
58.279  21.522 to
10.256  21.591
45.162  20.437 to
8.136  18.209
34.429  19.841 to
5.443  12.656
ANOVA, analysis of variance; EQ-5D, EuroQol five-dimensional; ES, effect size.
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Karnofsky Performance Scale and self-reported QOL.
Responsiveness to Change Over Time
Responsiveness is the sensitivity of a measure to known changes in
health over time. Here, this is examined in terms of sensitivity to
change in trial data before and after treatment across all study
arms. Responsiveness was examined by using floor and ceiling
effects, standardized response mean (SRM), ES, and t tests. Floor
and ceiling effects report the percentage of patients in either full
health or the most severe health state ‘‘PITS,’’ where a high
percentage indicates that the measure is unable to capture either
an improvement or a deterioration in health, respectively. Rela-
tive floor and ceiling effects are important as they indicate that
one measure cannot distinguish whereas another can. SRM is the
mean change score of a measure between two different time
points divided by the SD of the change score [30]. ES in this case is
the mean change score of a measure between two different time
points divided by the SD of the score at baseline. SRM and ES are
generated to assess the responsiveness of the different methods
between screening and cycle 9 of the trial and between screening
and end of treatment. These points were chosen as screening
represents the only period before treatment (n ¼ 604), cycle 9
represents the end of treatment for patients completing all
nine treatment cycles (n ¼ 283), and end of treatment includes
respondents at the end of their treatment (n ¼ 406). Follow-up
points were not used because of a large amount of missing data,
meaning that responses may not be representative of the study
population. Statistical significance of any difference was exam-
ined by using t tests. Utilities generated by using each method
were plotted by period to determine whether they show compar-
able movements in QOL throughout the trial. All statistics werereported by using all responses where observations were avail-
able for every measure of interest.Correlation and Agreement
The estimates produced by using the different methods were
compared by using Pearson correlation coefficients and
the intraclass correlation coefficient. Intraclass correlation coef-
ficient assesses the consistency of the methods given that they
are all generating utility values on the same 1-0 full health-
dead scale.Differences across Classification Systems
Further analysis was undertaken to determine why any differ-
ences in values were observed between the EQ-5D and the
EORTC-8D. This analysis can also be used to highlight whether
the measures have content validity for this patient group. If the
EQ-5D and the EORTC-8D produce different values, possible
explanations include classification system, preference weights
for the classification system, and recall period. The recall period
is likely to explain some difference as the EORTC-8D measures
health during the past week whereas the EQ-5D measures health
today. This is an issue for research using qualitative analysis and
is beyond the scope of this article. Further analysis was under-
taken here to explore differences due to the classification system.
Differences in the classification system were examined by
using Spearman rank correlations of each dimension of each
measure. Observed frequencies of each dimension are also
reported when each measure is at full health to determine
differences across the measures in ability to detect a health
improvement at the ceiling of the measure.
Table 2 (continued)
Range of mean  SD across groups Range of ES ANOVA
100 (n ¼ 557) 50–60 60–70 70–80 80–90 90–100
0.810  0.179 0.480 0.489 0.547 0.530 0.435 o0.001
0.852  0.122 0.462 0.497 0.396 0.354 0.699 o0.001
0.791  0.192 0.508 0.505 0.409 0.397 0.668 o0.001
0.879  0.195 0.445 0.570 0.484 0.540 0.688 o0.001
0.857  0.116 0.397 0.441 0.453 0.541 0.792 o0.001
81.029  23.532 to
88.480  15.500
0.261–0.494 0.209–0.608 0.104–0.614 0.063–0.657 0.148–0.701 o0.001
26.132  21.722 to
4.399  12.409
0.041–0.456 0.087–0.448 0.012–0.374 0.009–0.298 0.004–0.654 o0.001–0.001
69.045  17.775 0.299 0.499 0.343 0.348 0.476 o0.001
6 (n ¼ 947) 7 (n ¼ 215) 1–2 2–3 3–4 4–5 5–6 6–7
0.813  0.176) 0.885  0.184) 0.388 0.614 0.462 0.745 0.816 0.653 o0.001
0.871  0.097 0.918  0.086 0.550 0.865 0.553 0.770 0.586 0.811 o0.001
0.841  0.142 0.930  0.135 0.659 1.041 0.750 0.884 0.801 0.816 o0.001
0.960  0.114 1.080  0.126 0.946 1.461 1.194 1.348 1.237 1.116 o0.001
0.856  0.100 0.870  0.095 0.153 0.487 0.427 0.737 0.726 0.770 o0.001
83.062  16.453 to
90.549  16.458
88.419  15.470 to
95.039  12.215
0.045–0.447 0.475–0.859 0.351–0.503 0.279–0.680 0.343–0.706 0.406–0.664 o0.001
22.756  17.406 to
3.062  9.572
14.987  16.481 to
1.705  7.000
0.020–0.471 0.100–0.671 0.013–0.541 0.116–0.642 0.168–0.573 0.123–0.584 o0.001
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Discrimination
Severity groups were generated by using the Karnofsky Perfor-
mance Scale and overall QOL (using a QLQ-C30 item). The EORTC-
8D generally had higher ESs than the EORTC QLQ-C30 and similar
or higher ESs than the EQ-5D (Table 2). Mapped EQ-5D estimates
using the Mckenzie and van der Pol and Kontodimopoulos et al.
algorithms had higher ESs than the EQ-5D and the highest ESs
when severity groups were divided by overall QOL, most likely due
to the inclusion of the QLQ-C30 global health status in both
mapping algorithms. The Crott and Briggs–mapped EQ-5D esti-
mates, however, had generally higher ESs than the EQ-5D when
severity groups were divided by the Karnofsky Performance Scale
but lower ESs when severity groups were divided by overall QOL.
The difference in scores across adjacent severity groups was
statistically significant at the 1% level for all measures. The
EORTC-8D had a narrower range of mean values across severity
groups than did the EQ-5D (0.557–0.852 compared with 0.171–0.810
for severity groups defined by using the Karnofsky Performance
Scale). Despite these differences, the smaller SD of the EORTC-8D
resulted in similar or higher ESs than for the EQ-5D. Figure 1A,B
indicates that EORTC-8D values and the Crott and Briggs–mapped
EQ-5D estimates have a shallower gradient than do the other
methods, showing smaller differences across different severity
groups.Responsiveness
The range of utility values covered the full severity range for the
EQ-5D and the EORTC-8D, yet the mapped EQ-5D estimates did
not reflect the full range of severity at the lower end (Table 3). The
EQ-5D and mapped EQ-5D estimates had a much larger utility
range than did the EORTC-8D due to the differences in the utilityranges of the measures. The EQ-5D and the Kontodimopoulos
et al.–mapped estimates suffered from ceiling effects (12.8% and
11.4%, respectively). EORTC QLQ-C30 summary scores also suf-
fered from ceiling effects (up to 80.3% for one symptom summary
score), yet the EORTC-8D did not.
The mapped estimates had values above 1 as the mapping
algorithms used here were estimated by using OLS, meaning that
predictions are not constrained to 1. As EQ-5D values greater than
1 are impossible to obtain, this raises the issue of whether we
should censor mapped EQ-5D estimates above 1. Censoring the
values above 1 changes the mean and SD of the mapped esti-
mates, and although the change would be minimal for the
McKenzie and van der Pol and Crott and Briggs EQ-5D estimates,
this would produce a large change for the Kontodimopoulos et al.
EQ-5D estimates from 0.703 (0.250) to 0.695 (0.239). As the mapping
literature provides no guidance on this, the uncensored mapped
EQ-5D estimates were used in all analyses. The McKenzie and van
der Pol, Kontodimopoulos et al., and Crott and Briggs algorithms
correctly predicted (1 or above) 17.2%, 51.8%, and 7.3%, respec-
tively, of observed EQ-5D values at 1.
All methods used to produce utility values showed significant
differences in utilities between screening and cycle 9 and
between screening and end of treatment (Table 3). The size of
the change in utilities varied across methods, where the EQ-5D
showed the largest mean change with the largest SD
(0.189  0.337 between screening and cycle 9) and the EORTC-
8D showed the smallest mean change and the smallest SD
(0.049  0.145 between screening and cycle 9). For the methods
used to produce utilities, the ESs and SRMs were largest for the
Kontodimopoulos et al. estimates and smallest for the EORTC-8D.
ESs and SRMs for the EORTC-8D were toward the upper range
produced for EORTC QLQ-C30 summary scores, which may
be expected given that the EORTC-8D is made up of 10 EORTC
QLQ-C30 items. Overall, the EORTC QLQ-C30 global QOL summary
score had the highest ES and SRM. Figure 1C indicates that there
was a noticeable gap between the utilities for the EQ-5D
Fig. 1 – Discrimination across severity groups and mean
utility values by period. (A) Discrimination across severity
groups by Karnofsky Performance Scale. (B) Discrimination
across severity groups by overall quality of life. (C) Utility
values by period. Note. no 40 for Karnofsky Performance
Scale o 60, and so it is not reported for 1A. EQ-5D, EuroQol
five-dimensional.
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always higher. The McKenzie and van der Pol–mapped EQ-5D
estimates followed a pattern similar to the EQ-5D, whereas the
Kontodimopoulos et al. and Crott and Briggs estimates followed a
pattern similar to the EORTC-8D.
The mapped EQ-5D estimates had a lower SD than observed
EQ-5D estimates, and this has been observed elsewhere in the
mapping literature. Mapped values contain an error, measured as
the difference between predicted and observed values. Mean
absolute error (MAE) was 0.144 for the McKenzie and van der
Pol estimates, 0.156 for the Kontodimpopoulos et al. estimates,
and 0.177 for the Crott and Briggs estimates. Error in predictions
increased for more severe health states (analysis not reported,
available on request), where MAE was more than doubled when
the observed EQ-5D value was less than 0.5 compared with EQ-5D
value greater than or equal to. 0.5, and a similar pattern has been
previously observed in the mapping literature [31]. The pattern
was most severe for the Crott and Briggs estimates with an MAE
of 0.442 when the observed EQ-5D value was less than 0.5.Correlation and Agreement
Utility values generated by using each of the values had high
correlation coefficients (Table 4), yet the mapped estimates were
more highly correlated with the EORTC-8D than with the EQ-5D.
This is perhaps unsurprising given that the mapped estimates and
the EORTC-8D were all generated by using QLQ-C30 responses but
has not been explored in the mapping literature previously.
Differences across Classification System
The above analysis demonstrated differences in the EQ-5D and
EORTC-8D utilities. The EQ-5D and EORTC-8D dimensions were
most highly correlated where expected, such as EQ-5D pain/
discomfort and EORTC-8D pain (Table 5). The correlations were
below 0.5 between all EQ-5D dimensions and EORTC-8D fatigue,
nausea, and constipation/diarrhea dimensions and between EQ-
5D self-care and all EORTC-8D dimensions. This suggests differ-
ences in the QOL captured by the two classification systems for
these dimensions.
Table 6 summarizes EORTC-8D responses when the EQ-5D
value ¼ 1, meaning that the respondent is in full health, demon-
strating that the EORTC-8D captured an impact on QOL according
to dimensions such as fatigue and physical functioning that are
not captured in the EQ-5D for these patients. This is most
noticeable for fatigue, where 52.77% of the observations at EQ-
5D full health had fatigue in the EORTC-8D; similarly, 45.71% of
the observations had problems in the physical functioning
dimension. Table 7 summarizes EQ-5D responses when the
EORTC-8D value ¼ 1, meaning that the respondent was in full
health, finding that the EQ-5D captured some differences in pain/
discomfort and anxiety/depression not captured by the EORTC-
8D, but the proportion of these responses was small (14.08% and
9.23%, respectively).Discussion
Generic EQ-5D, condition-specific EORTC-8D, and two published
mapping algorithms were used to generate utility estimates for
patients with multiple myeloma in a clinical trial data set. We
observed differences in mean utilities and in mean change across
time periods by using the different methods, with the EQ-5D
consistently showing the largest mean utility gain. However, all
methods were able to discriminate between severity groups
measured by using the Karnofsky Performance Scale and an
overall QOL item and were responsive. We further compared the
performance of the EORTC-8D with the EORTC QLQ-C30 measure
it was derived from, finding that discriminative validity and
responsiveness of the EORTC-8D was comparable to that of
QLQ-C30 functioning and symptom summary scores but inferior
to the QLQ-C30 global QOL summary score. The QLQ-C30 global
QOL score was excluded from the health state classification
system of the EORTC-8D because it is inappropriate for inclusion
in a multiattribute preference-based measure yet was included in
both the McKenzie and van der Pol [15] and Kontodimopoulos
et al. [20] mapping algorithms and their discriminative validity
and responsiveness may in part be attributed to this. Analyses
have been conducted by using one patient data set containing
patients with one type of cancer, and this is a limitation of this
research. Replicating these analyses by using data for other
cancer types is recommended.
The analysis has been performed by using observations with
no missing data for any of the approaches used to generate
utilities or EORTC QLQ-C30 summary scores. However, high levels
of missing data mean that the utilities are not representative of
the entire trial sample, and this is important as the data may be
missing for systematic reasons where patients in the poorest
Table 3 – Responsiveness.
All (n ¼ 5650) Screening to cycle 9 (n ¼ 255) Screening to end of treatment (n ¼ 370)
Min Max % at
worst
state
% at
(or
above)
full
health
Mean
change  SD
SRM ES Paired t test
(P)
Mean
change  SD
SRM ES Paired t test
(P)
EQ-5D 0.594 1.000 0.02 12.8 0.189  0.337 0.559 0.524 o0.001 0.100  0.371 0.270 0.279 o0.001
EORTC-8D 0.291 1.000 0.001 3.6 0.049  0.145 0.338 0.325 o0.001 0.021  0.154 0.137 0.140 0.009
McKenzie and van
der Pol–mapped
EQ-5D
estimates
0.268 1.051 0 2.5 0.137  0.276 0.495 0.482 o0.001 0.078  0.289 0.271 0.276 o0.001
Kontodimopoulos
et al.–mapped
EQ-5D
estimates
0.181 1.186 0 11.4 0.154  0.263 0.586 0.552 o0.001 0.084  0.302 0.278 0.301 o0.001
Crott and
Briggs–mapped
EQ-5D
estimates
0.238 1.147 0 3.3 0.099  0.214 0.463 0.426 o0.001 0.062  0.223 0.277 0.265 o0.001
EORTC QLQ-C30
functioning
summary
scores
0 100 0.5–8.4 7.4–35.0 0.523  20.909 to 11.035  24.871 0.025–0.444 0.023–0.431 o0.001–0.690 1.216  22.341 to
5.563  26.418
0.041–0.211 0.042–0.228 o0.001–0.100
EORTC QLQ-C30
symptom
summary
scores
100 0 0.7–5.4 8.1–80.3 1.569  22.665 to 18.039  33.321 0.069 to
0.541
0.105 to
 0.540
o0.001–0.270  1.441  19.269
to
14.054  34.301
 0.075 to
 0.410
 0.088 to
 0.422
o0.001
–0.426
EORTC QLQ-C30
global QOL
summary score
0 100 1.7 2.6 14.705  25.108 0.586 0.664 o0.001 9.437  26.532 0.356 0.413 o0.001
EQ-5D, EuroQol five-dimensional; ES, effect size; QOL, quality of life; SRM, standardized response mean.
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Table 5 – Correlation by dimension (n ¼ 5650).
Spearman rank correlation EQ-5D dimensions
EORTC-8D dimensions Mobility Self-care Usual activities Pain/discomfort Anxiety/depression
Physical functioning 0.599 0.444 0.610 0.428 0.287
Role functioning 0.536 0.482 0.654 0.431 0.314
Pain 0.502 0.437 0.560 0.613 0.332
Emotional functioning 0.260 0.267 0.343 0.303 0.626
Social functioning 0.452 0.422 0.588 0.386 0.334
Fatigue 0.424 0.323 0.496 0.383 0.342
Nausea 0.204 0.194 0.244 0.207 0.216
Constipation and diarrhea 0.219 0.233 0.268 0.255 0.228
EQ-5D, EuroQol five-dimensional.
Table 6 – EORTC-8D responses when the EQ-5D ¼ 1 (n ¼ 722).
EORTC-8D dimensions %
Level 1 Level 2 Level 3 Level 4 Level 5
Physical functioning 54.29 37.12 7.76 0.83 0
Role functioning 77.01 20.91 1.94 0.14 NA
Pain 88.09 11.50 0.42 0 NA
Emotional functioning 85.04 14.27 0.28 0.42 NA
Social functioning 82.83 15.65 1.39 0.14 NA
Fatigue 47.23 48.06 4.57 0.14 NA
Nausea 92.94 6.51 0.14 0.42 NA
Constipation and diarrhea 69.39 25.48 3.74 1.39 NA
EQ-5D, EuroQol five-dimensional; NA, not applicable.
Table 4 – Correlation and agreement.
Measures Pearson
correlation
coefficient
ICC mean (95%
confidence interval)
ICC P
value
EQ-5D and EORTC-8D 0.713 0.481 (0.263–0.624) o0.001
EQ-5D and McKenzie and van der Pol–mapped EQ-5D estimates 0.757 0.749 (0.737–0.760) o0.001
EQ-5D and Kontodimopoulos et al.–mapped EQ-5D estimates 0.749 0.713 (0.626–0.775) o0.001
EQ-5D and Crott and Briggs–mapped EQ-5D estimates 0.709 0.570 (0.327–0.711) o0.001
EORTC-8D and McKenzie and van der Pol–mapped EQ-5D estimates 0.933 0.638 (0.072–0.832) o0.001
EORTC-8D and Kontodimopoulos et al.–mapped EQ-5D estimates 0.875 0.721 (0.646–0.775) o0.001
EORTC-8D and Crott and Briggs–mapped EQ-5D estimates 0.785 0.751 (0.740–0.762) o0.001
McKenzie and van der Pol–mapped EQ-5D estimates and
Kontodimopoulos et al.–mapped EQ-5D estimates
0.921 0.868 (0.517–0.943) o0.001
McKenzie and van der Pol–mapped EQ-5D estimates and Crott and
Briggs–mapped questionnaire EQ-5D estimates
0.819 0.656 (0.148–0.833) o0.001
Kontodimopoulos et al.–mapped EQ-5D estimates and Crott and
Briggs–mapped EQ-5D estimates
0.768 0.719 (0.659–0.765) o0.001
EQ-5D, EuroQol five-dimensional; ICC, intraclass correlation coefficient.
VA L U E I N H E A LT H 1 5 ( 2 0 1 2 ) 1 0 5 9 – 1 0 6 81066health are unable to complete the appropriate questionnaire.
Missing values for the overall data set did vary by method, where
overall the Crott and Briggs estimates had the smallest propor-
tion of missing values (1.9%) followed by Kontodimopoulos et al.
estimates (2.2%), and the EQ-5D (2.8%) with the EORTC-8D (4.4%)
and the McKenzie and van der Pol estimates (5.1%) having the
largest proportions.
Mapping is advantageous as it enables EQ-5D utilities to be
estimated when the EQ-5D was not included in the trial. How-
ever, these mapped values contain an error and should beconsidered only as a second best alternative to including the
EQ-5D directly in the trial. Here, the McKenzie and van der Pol
[12] algorithm produced more accurate EQ-5D estimates than did
the Kondimopoulos et al. [20] and Crott and Briggs [21] algo-
rithms, yet all have a high MAE. The Crott and Briggs–mapped
EQ-5D estimates had poorer performance than the McKenzie and
van der Pol and Kontodimopoulos et al.–mapped EQ-5D estimates
in terms of responsiveness, discriminative ability, and correlation
and agreement with the EQ-5D and had much higher MAE when
the observed EQ-5D value was less than 0.5. The reasons behind
Table 7 – EQ-5D responses when EORTC-8D ¼ 1 (n ¼ 206).
EQ-5D dimensions %
Level 1 Level 2 Level 3
Mobility 96.60 3.40 0
Self-care 99.03 0.97 0
Usual activities 99.51 0.49 0
Pain/discomfort 85.92 14.08 0
Anxiety/depression 90.78 8.74 0.49
EQ-5D EuroQol five-dimensional.
VA L U E I N H E A LT H 1 5 ( 2 0 1 2 ) 1 0 5 9 – 1 0 6 8 1067this are unclear. The Crott and Briggs algorithm was estimated by
using a data set from a multicenter, multicountry prospective
clinical trial of female patients with breast cancer, with a low
number of observations at low utility levels and a lowest EQ-5D
utility value of 0.239 [21]. It is possible that these multiple
differences in the data set used to estimate the mapping algo-
rithm and the multiple myeloma patient data set used here may
account for the differences, as for mapping to provide accurate
and appropriate estimates the patient group used to estimate the
mapping algorithm should be representative of the patient group
it is applied to. Longworth and Rowen [14] recommend that
articles estimating mapping algorithms include the distribution
of utility values and explanatory variables so that users of the
algorithm can determine whether they are generating extrapo-
lated EQ-5D values in their data set. The Crott and Briggs
algorithm was estimated by using a data set with a smaller range
of EQ-5D values than the multiple myeloma data set, but the
range of explanatory variables was not included in the article.
The Kontodimopoulos et al. algorithm was estimated by using a
data set with a smaller range of values for the EQ-5D and some
explanatory variables than the multiple myeloma data set used
here. In contrast, the McKenzie and van der Pol algorithm was
estimated on a data set with the full range of values for the EQ-5D
and the explanatory variables. In general, this also highlights the
need for the validation of mapping algorithms by using external
data sets, as although all the mapping algorithms were validated,
only the McKenzie and van der Pol algorithm was validated by
using an external sample where the characteristics of the data set
may vary.
We suggest that EORTC-8D utilities are more accurate than
these mapped estimates as they do not contain an error, yet
recognize that they are less comparable to the observed EQ-5D
utilities. NICE suggests that the mapped estimates should be
presented in the main economic evaluation analyses and EORTC-
8D utilities should be included in a separate analysis [6]. NICE
further recommend that when using condition-specific measures
such as the EORTC-8D, researchers should indicate the extent to
which their choice of instrument has impacted on the valuations.
Our findings suggest that the use of the EORTC-8D would
generate lower mean change in utilities with smaller SD than
the use of the EQ-5D to generate utilities for the same cancer
patient group.
NICE recommends using the same valuation methodology as
the UK valuation of the EQ-5D to ensure comparability with the
EQ-5D when using condition-specific measures to produce uti-
lities for use in economic evaluation [6]. Yet differences between
the EQ-5D and the EORTC-8D were observed despite the EORTC-
8D using the same valuation methodology as the UK Measuring
and Valuing Health study valuation of the EQ-5D [10]. Further
analysis suggested that some of the differences were due to the
classification system. However, it is possible that some of the
differences were due to the preference weights.Here, we have not analyzed the impact that these differences
have on QALY estimates. It is possible that the differences in
utility values will have an impact on QALY estimates and change in
QALY estimates, particularly where survival differs across interven-
tions. Two studies have compared mapped estimates with direct
EQ-5D estimates for use to generate QALYs in economic evaluation
[15,16]. Although both studies found no significant difference
between QALY estimates generated by using mapping to the EQ-
5D and directly observed EQ-5D values, one of these studies found
that incremental cost per QALY estimates differed across four
interventions depending on whether mapped or directly observed
EQ-5D values were used [16]. Research analyzing the impact on
QALYestimates from using generic or condition-specific preference-
based measures is recommended.
The EQ-5D is not always included in cancer trials, sometimes
because it is thought to be inappropriate or unresponsive. In
contrast, condition-specific measures are often included, as they
are thought appropriate and responsive. Here, the EQ-5D has
higher responsiveness than the condition-specific EORTC-8D and
was also able to discriminate between severity groups by using
the Karnofsky Performance Scale and an overall QOL item from
the QLQ-C30. This raises the issue of why it is thought that the
EQ-5D is inappropriate for capturing change in patients with
cancer, despite our findings that it is responsive and able to
discriminate between severity groups. Our findings suggest that
it may be due to content validity, as here 12.8% of EQ-5D
responses are at full health whereas for a large proportion of
these observations the EORTC-8D captures problems on dimen-
sions such as fatigue and physical functioning. This indicates
problems with content validity, yet this can be appropriately
determined only by using qualitative analysis, which is beyond
the scope of this article. This raises the issue of how to determine
whether the EQ-5D is inappropriate and whether it is sufficient
that it is able to detect a change. Guidance suggests that it is not
simply a question of ability to detect a change. Content validity
has an important role in the new US Food and Drug Administra-
tion guidance on patient-reported outcomes for use in labeling
claims [8], a recent report on economic evaluations in cancer
found that the EQ-5D did not contain all domains thought
important for sensitivity in an outcome measure for patients
with cancer [7], and NICE states that evidence used to demon-
strate that the EQ-5D is inappropriate can cover content validity
as well as construct validity, responsiveness, and reliability [6].
The use of the EQ-5D-5L, which has five severity levels rather
than three for each dimension, rather than the EQ-5D in future
studies may lead to fewer responses at full health and may lead
to greater responsiveness and discriminative ability. The EQ-5D-
5L, however, may not have improved content validity as the
dimensions do not change but only the number of severity levels,
and further research in this area is encouraged.
The recommendation of one generic measure such as the EQ-
5D for use in all economic evaluations is advantageous for
comparability but raises issues of best practice when this mea-
sure is unavailable or inappropriate. Recommended alternatives
are to use mapped estimates or other preference-based mea-
sures. As far as we are aware, this is the first article to compare
utility values generated by using the EQ-5D, a condition-specific
preference-based measure, and published mapping algorithms.
Our analysis for a multiple myeloma cancer patient data set
suggests that all methods were able to discriminate across
severity groups and were responsive but that the mean change
and SD across time periods or severity groups was affected by the
alternative method used. The condition-specific preference-
based measure and published mapping algorithms produced
lower mean change and SD than the use of the EQ-5D directly.
Mapped estimates contain an error, and this will affect the
accuracy of the utility estimates. In contrast, EORTC-8D estimates
VA L U E I N H E A LT H 1 5 ( 2 0 1 2 ) 1 0 5 9 – 1 0 6 81068did not contain an error and captured problems in QOL at the
upper end of the utility scale that were not captured by the EQ-
5D, but overall produced higher utility estimates and smaller
mean change. The preference-based EORTC-8D performed com-
parably to the non–preference-based EORTC QLQ-C30 measure it
was derived from. Further research is encouraged to determine
whether similar results are found using data sets for other types
of cancer and for other condition-specific preference-based
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